The results demonstrated that Notch3-based PRSM could achieve more net benefits compared with other prognostic variables for almost all threshold probabilities in both the training and validation cohorts (Figure 6C), suggesting that Notch3-based PRSM showed a better-predictive performance for primary GBM patient’s survival. Here, NOTCH3 is linked to glioblastoma.